Lasagna A, Cambieri P, Figini S, Baldanti F, Andreoni M, Perrone F, Silvestris N, Pedrazzoli P
Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Department of Microbiology and Virology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
JAC Antimicrob Resist. 2025 Aug 18;7(4):dlaf150. doi: 10.1093/jacamr/dlaf150. eCollection 2025 Aug.
Infections with antimicrobial-resistant (AMR) organisms significantly worsen outcomes in cancer patients. Since the main cause of AMR is the inappropriate use of antibiotics for prophylactic or empirical treatment, antimicrobial stewardship programmes (ASPs) have been developed. Few papers on ASPs describe prospective audits in oncology settings. In light of this, the Italian Association of Medical Oncology (AIOM) has decided to evaluate the oncologists' perceptions of this issue with a brief survey.
An anonymous 14-item questionnaire was shared online during the XXVI National Congress on the AIOM website. The survey was divided into two sections. The first set of questions collected the hospital organization and practices (Q1-Q6), while the second one was about the clinical practices and antibiotic therapy (Q7-Q14).
Sixty-four medical oncologists completed the anonymous questionnaire. Seventy-two percent of respondents believe that AMR is a significant issue in cancer patients, and an equal percentage considers it likely that a cancer patient will become infected with a MDR pathogen. Despite these concerns, only 48% ( = 31/64) report having an active ASP in their centre. Just 6% of respondents ( = 4/64) consider themselves very confident in prescribing antibiotic therapy, while most consider themselves fairly or not very confident ( = 34/64, 53%, and = 26/64, 36%, respectively).
This survey highlights the urgent need for educating and training oncologists on AMR, as well as the importance of the development of oncology-specific guidelines to mitigate the impact of AMR in this high-risk population.
抗菌药物耐药（AMR）微生物感染会显著恶化癌症患者的治疗结果。由于AMR的主要原因是预防性或经验性治疗中抗生素的不当使用，因此已制定了抗菌药物管理计划（ASP）。很少有关于ASP的论文描述肿瘤学环境中的前瞻性审计。有鉴于此，意大利医学肿瘤学协会（AIOM）决定通过一项简短调查来评估肿瘤学家对这一问题的看法。
在第26届全国大会期间，一份包含14个项目的匿名问卷在AIOM网站上在线分享。该调查分为两个部分。第一组问题收集医院组织和实践情况（问题1 - 6），而第二组问题是关于临床实践和抗生素治疗（问题7 - 14）。
64名医学肿瘤学家完成了这份匿名问卷。72%的受访者认为AMR在癌症患者中是一个重要问题，并且同样比例的人认为癌症患者有可能感染多重耐药病原体。尽管存在这些担忧，但只有48%（= 31/64）报告其所在中心有活跃的ASP。只有6%的受访者（= 4/64）认为自己在开具抗生素治疗方面非常有信心，而大多数人认为自己有一定信心或信心不足（分别为34/64，53%，以及26/64，36%）。
这项调查凸显了迫切需要对肿瘤学家进行AMR方面的教育和培训，以及制定针对肿瘤学的指南以减轻AMR对这一高危人群影响的重要性。
